Korean Circ J.  2007 Aug;37(8):353-358. 10.4070/kcj.2007.37.8.353.

The Association of Osteoprotegerin with Cardiovascular Disease and the New York Heart Association Classification

• Sung KC
• Kwon CH
• Rhee EJ
• Kim BJ
• Kim BS
• Kang JH

• KMID: 2029062
• DOI: http://doi.org/10.4070/kcj.2007.37.8.353

Abstract

BACKGROUND AND OBJECTIVES: Recent studies have suggested that there is a significant correlation between elevated serum Osteoprotegerin (OPG) levels and cardiovascular diseases. We investigated whether the serum OPG levels were associated with heart failure (HF), acute myocardial infarction (AMI) and unstable angina (UA), and whether the serum OPG levels were correlated with the NYHA classifications.
SUBJECTS AND METHODS
The serum OPG levels were measured in 127 patients suffering with HF, AMI and UA and they were hospitalized in the cardiology department, and these values were compared to 63 healthy controls. The NYHA classification was used to define the clinical disease severity. The serum OPG level was measured by performing ELISA.
RESULTS
The serum OPG levels were significantly higher in the patients with HF and AMI than those in the control subjects (p=0.003, p=0.002, respectively). The mean OPG levels were 555, 683, 774 and 856 pg/mL for the subjects and controls, according to the NYHA classifications II, III and IV, respectively. Multiple regression analysis revealed that the serum OPG levels were significantly associated with HF and AMI, and when all subjects were regrouped according to NYHA classification, the serum OPG levels were also significantly associated with the NYHA classification.
CONCLUSION
The serum OPG levels were increased in Asian patients suffering with cardiovascular disease such as HF and AMI, and they were also increased with the NYHA classification. The serum OPG level could be a marker for different stages of cardiovascular disease.

Keyword

Osteoprotegerin; Cardiovascular diseases; Heart failure, congestive

MeSH Terms

Angina, Unstable
Asian Continental Ancestry Group
Cardiology
Cardiovascular Diseases*
Classification*
Enzyme-Linked Immunosorbent Assay
Heart Failure
Heart*
Humans
Myocardial Infarction
Osteoprotegerin*
Osteoprotegerin

Figure

• 

  Fig. 1 The serum OPG level (pg/mL) according to the NYHA classification. OPG: osteoprotegerin, NYHA: New York Heart Association.

Reference

1. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000. 15:2–12.

2. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet. 2001. 358:257–259.

3. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998. 12:1260–1268.

4. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001. 21:1610–1616.

5. Hofbauer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. 2001. 280:334–339.

6. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000. 275:20959–20962.

7. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001. 21:1998–2003.

8. Park CS, Youn HJ, Choi YS, et al. Plasma osteoprotegerin level, a new biochemical marker of atherosclerosis, is associated with diabetes mellitus and age in coronary artery Disease. Korean Circ J. 2006. 36:543–548.

9. Park CS, Chung WS, Youn HJ, et al. Association between the serum osteoprotegerin level and target lesion calcium in coronary artery disease. Korean Circ J. 2006. 36:337–342.

10. Rhee EJ, Lee WY, Kim SY, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci. 2005. 108:237–243.

11. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001. 86:631–637.

12. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004. 109:2175–2180.

13. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004. 44:1970–1976.

14. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined. J Am Coll Cardiol. 2000. 36:959–969.

15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002. 106:1893–1900.

16. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993. 22(4):Suppl A. 6A–13A.

17. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005. 111:2461–2468.

18. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002. 22:549–553.

19. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998. 273:14363–14367.

20. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004. 35:1636–1641.

21. Moran CS, McCann M, Karan M, Norman P, Keteesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005. 111:3119–3125.

22. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med. 2002. 12:97–101.

23. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002. 90:520–530.

24. Kim TK, Chae SC, Yang DH, et al. Short-term prognostic value of CRP in the patients with acute coronary syndrome. Korean Circ J. 2000. 30:1387–1394.

25. Koo BK, Choi D, Kyung HD, et al. Role of inflammation in stable angina patients without hypercholesterolemia. Korean Circ J. 2001. 31:620–624.

26. Kim KH, Jeong MH, Shin JH, et al. The role of chronic infection and inflammation in Korean patients with coronary artery disease. Korean Circ J. 2000. 30:1107–1116.

27. Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002. 521:180–184.